Background: The release of incretin based therapeutic entities has brought the possibility to offer control of the disease by augmenting a natural process in the body that has become deficient with type 2 diabetes. Liraglutide, an incretin mimetic, and saxagliptin, a dipeptidyl peptidase-4 inhibitor, have been approved and introduced to the market.
Objectives: To (a) review the efficacy and safety data of for the treatment of type 2 diabetes, and (b) recommend their place in therapy.
Methods: A MEDLINE search was performed using key words "liraglutide" and "saxagliptin" for articles published and available through July 2010.
Results: The Liraglutide Effect and Action in Diabetes (LEAD) trials encompassed six published phase 3 trials that evaluated the efficacy and safety of liraglutide either as monotherapy or in addition to oral hypoglycemic medications. Saxagliptin has been studied as monotherapy and in combination to oral hypoglycemic medications.
Conclusions: Liraglutide has been shown to improve glucose control and weight loss compared to other pharmacologic treatments with diabetes and may offer improved control with a decrease in daily dosing compared to exenatide. Saxagliptin improved glucose control as monotherapy or in combination with medications other than sulfonylurea. Saxagliptin has not been evaluated head to head with sitagliptin other than in combination with metformin where saxagliptin was deemed noninferior. Given the lack of long-term safety and clinical data compared to current treatment modalities, and more importantly the overall cost of the therapies to the health care system, a global recommendation for their use cannot be issued.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SMJ.0b013e318215fc7a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
N1 derived lipoteichoic acid alleviates insulin resistance in association with modulation of the gut microbiota and amino acid metabolism.
Food Funct
January 2025
College of Food Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China.
This study aimed to investigate the effects of heat-killed N1 (HK-N1) and lipoteichoic acid (LTA) derived from it on alleviating insulin resistance by modulating the gut microbiota and amino acid metabolism. High-fat diet (HFD)-fed mice were administered live bacteria or HK-N1, and the results demonstrated that HK-N1 significantly reduced epididymal adipocyte size and serum low density lipoprotein-cholesterol, and improved insulin resistance by increasing the YY peptide and glucagon-like peptide levels. HK-N1 also modulated the gut microbiome composition, enhancing microbiota uniformity and reducing the abundance of , and .
View Article and Find Full Text PDFBudget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand.
Front Public Health
January 2025
Rajavithi Hospital, College of Medicine, Ministry of Public Health, Rangsit University, Bangkok, Thailand.
Objective: This study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer's perspective.
Methods: The budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar treatment by comparing the total budget expenditures under two scenarios: scenario 1 involved only NPH insulin and scenario 2 included the introduction of IGlar. The total budget included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia.
The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014.
Front Endocrinol (Lausanne)
January 2025
Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Wuxi, Jiangsu, China.
Background: Previous research has indicated that long working hours are connected to a variety of health conditions, including nonalcoholic fatty liver disease (NAFLD). However, this association which has been observed in more population is limited. Our research is designed to evaluate the association between working hours, working type, and NAFLD.
View Article and Find Full Text PDFPhysician-Visit Frequency and Its Impact on Glycemic Control in People With Type 2 Diabetes: Quantifying Care Acceptance Parameters From Retrospective Electronic Health Record Data.
Cureus
December 2024
Obstetrics and Gynecology, Shree Guru Gobind Singh Tricentenary University Medical College, Hospital and Research Institute, Gurugram, IND.
Objective: Type 2 diabetes is a metabolic disorder characterized by insulin resistance and hyperglycemia affecting many individuals worldwide. For effective management, adherence to recommended physician visits is important, along with lifestyle modification and pharmacological interventions. Regular doctor visits can improve adherence and help prevent complications.
View Article and Find Full Text PDFExploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.
World J Gastroenterol
January 2025
Université de Bourgogne, Institut Agro-INRAe, Dijon 21000, France.
The recent study exploring the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease highlights a critical concern in chronic disease management. Given the rising global prevalence of these conditions, understanding their interconnections is essential. The study emphasizes the importance of shared risk factors, such as obesity, type 2 diabetes, dyslipidemia, and oxidative stress, and calls for multidisciplinary screening strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!